There are still weeks left in this year’s flu season, according to the FDA, but the agency is already planning on how to better protect the nation’s public health next year.
An initial report from the Centers for Disease Control and Prevention concluded that this year’s flu vaccine sported a 36% efficacy rate. Although that’s better than some public health experts predicted, FDA chief Dr. Scott Gottlieb said in a statement that “there is still clearly significant room for improvement.”
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.